Profile (CV) of the research teaching staff

Antón Torres, Antonio
Department: Departamento de Medicina, Psiquiatría y Dermatología
Field: Medicina
Faculty: Facultad de Medicina

Research Institute: INSTITUTO INVESTIGACIÓN SANITARIA DE ARAGÓN (IIS)
Academic position: Prof. Titular Univ.
ORCID number: 0000-0002-9159-4988

University degrees
  • Especialista en Oncología Médica. Hospital Clínico Universitario de Valencia. 1985
  • Licenciatura Medicina y Cirugia. Universitat de València. 1980

PhDs
  • Doctor en Medicina y Cirugía Facultad de Medicina Universidad de Valencia. Facultad de Medicina y Odontología. 1993

Download curriculum in PDF format Go to ORCID page

 
           

Journal articles

  • Lope, Virginia; Guerrero-Zotano, Ángel; Fernández de Larrea-Baz, Nerea; Antolín, Silvia; Benavent Viñuales, Marta; Bermejo, Begoña; Ruiz-Moreno, Emma; Baena-Cañada, José Manuel; París, Lorena; Antón, Antonio; Chacón, José Ignacio; Muñoz, Montserrat; García-Sáenz, José Ángel; Olier, Clara; Sánchez Rovira, Pedro; Arcusa Lanza, Àngels; González, Sonia; Brunet, Joan; Oltra, Amparo; Bezares, Susana; Rosell, Libertad; Pérez-Gómez, Beatriz; Pastor-Barriuso, Roberto; Martín, Miguel; Pollán, Marina. Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study. JOURNAL OF NUTRITION, HEALTH AND AGING. 2024. DOI: 10.1016/j.jnha.2024.100312

  • Rietjens, Judith A. C.; Griffioen, Ingeborg; Sierra-Pérez, Jorge; Sroczynski, Gaby; Siebert, Uwe; Buyx, Alena; Peric, Barbara; Svane, Inge Marie; Brands, Jasper B. P.; Steffensen, Karina D.; Romero Piqueras, Carlos; Hedayati, Elham; Karsten, Maria M.; Couespel, Norbert; Akoglu, Canan; Pazo-Cid, Roberto; Rayson, Paul; Lingsma, Hester F.; Schermer, Maartje H. N.; Steyerberg, Ewout W.; Payne, Sheila A.; Korfage, Ida J.; Stiggelbout, Anne M.; Oliveira, Claudia Cruz; Semino, Elena; Roobol, Monique; López-Forniés, Ignacio; Kunneman, Marleen; Verberne, Suzan; Kuld, Anne; Van Mulligen, Erik M.; Knudsen, Bettina Mølri; Kors, Jan A.; Venderbos, Lionne D. F.; Donia, Marco; Koppert, Linetta B.; Nwosu, Amara C.; Verheul, Elfi M.; Sañudo, Yeray; Kremer, Marie; Gracia, Jorge; Antón, Antonio; Schreijer, Maud; Bangma, Chris; Hartman, Laura; Van Klaveren, David; Aiger Valles, Monserrat; Pitarch, Lucia; Hallsson, Lara R.; Wouters, Michel; Kapiteijn, Ellen; de Glas, Nienke; Van Buchem, Marieke; Doornkamp, Frank; Borštnar, Simona; Wee, Leonard; Pross, Therese; Silva, Marta; Venegoni, Enea; Lorenzo, Nora; Wallberg, Susanne; Dankl, Kathrina; de Jesús, Teresa Puértolas; Romera, Juan Lao; Pons, Paula Gomila; Signerez, Paula Melo; Secomandi, Fernando; Snelders, Dirk: On Behalf Of 4d Picture Consortium. Improving shared decision-making about cancer treatment through design-based data-driven decision-support tools and redesigning care paths: an overview of the 4D PICTURE project. PALLIATIVE CARE AND SOCIAL PRACTICE. 2024. DOI: 10.1177/26323524231225249

  • Martín, Miguel; Carrasco, Eva; Rodríguez-Lescure, Álvaro; Andrés, Raquel; Servitja, Sonia; Antón, Antonio; Ruiz-Borrego, Manuel; Bermejo, Begoña; Guerrero, Ángel; Ramos, Manuel; Santaballa, Ana; Muñoz, Montserrat; Cruz, Josefina; Lopez-Tarruella, Sara; Chacón, Jose I.; Álvarez, Isabel; Martínez, Purificación; Miralles, Juan J.; Polonio, Óscar; Jara, Carlos; Aguiar-Bujanda, David. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry. BREAST CANCER RESEARCH AND TREATMENT. 2023. DOI: 10.1007/s10549-023-07002-1

  • Pascual, Javier; Gil-Gil, Miguel; Proszek, Paula; Zielinski, Christoph; Reay, Alistair; Ruiz-Borrego, Manuel; Cutts, Rosalind; Ciruelos Gil, Eva M.; Feber, Andrew; Muñoz-Mateu, Montserrat; Swift, Claire; Bermejo, Begoña; Herranz, Jesus; Margeli Vila, Mireia; Antón, Antonio; Kahan, Zsuzsanna; Csöszi, Tibor; Liu, Yuan; Fernandez-Garcia, Daniel; Garcia-Murillas, Isaac; Hubank, Michael; Turner, Nicholas C.; Martín, Miguel. Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients. CLINICAL CANCER RESEARCH. 2023. DOI: 10.1158/1078-0432.CCR-23-0956

  • Camps C.; López R.; Antón Torres, A.; Aranda E.; Carrato A.; Cruz J.J.; Cunquero-Tomás A.J.; Díaz-Rubio E.; Feyjóo M.; García-Foncillas J.; Gascón P.; Lugo I.; Rogado Á.; Guillem V. Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications. JCO ONCOLOGY PRACTICE. 2021. DOI: 10.1200/OP.20.00683

  • Martin, M.; Zielinski, C.; Ruiz-Borrego, M.; Carrasco, E.; Turner, N.; Ciruelos, E.M.; Muñoz, M.; Bermejo, B.; Margeli, M.; Anton, A.; Kahan, Z.; Csöszi, T.; Casas, M.I.; Murillo, L.; Morales, S.; Alba, E.; Gal-Yam, E.; Guerrero-Zotano, A.; Calvo, L.; de la Haba-Rodriguez, J.; Ramos, M.; Alvarez, I.; Garcia-Palomo, A.; Huang Bartlett, C.; Koehler, M.; Caballero, R.; Corsaro, M.; Huang, X.; Garcia-Sáenz, J.A.; Chacón, J.I.; Swift, C.; Thallinger, C.; Gil-Gil, M. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL. ANNALS OF ONCOLOGY. 2021. DOI: 10.1016/j.annonc.2020.12.013

  • López, R.; Borrega, P.; Antón, A.; Aranda, E.; Carrato, A.; Constenla, M.I.; Cruz, J.J.; Díaz-Rubio, E.; Feyjóo, M.; García-Foncillas, J.; Gascón, P.; Guillem, V.; Camps, C. Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain [Manejo y percepción de la adherencia al tratamiento del dolor irruptivo oncológico por oncólogos españoles]. REVISTA DE LA SOCIEDAD ESPAÑOLA DEL DOLOR. 2021. DOI: 10.20986/RESED.2021.3824/2020

  • Guerrero-Zotano, A.; Jara, C.; Lopez-Tarruella, S.; Rodriguez, C.A.; Adrover, E.; Falo, C.; Martinez, P.; Antolin, S.; Margeli, M.; Cruz, J.; Rodriguez-Lescure, A.; Iranzo, V.; Gomez-Raposo, C.; Illarramendi, J.J.; Malon, D.; Alonso, J.L.; Anton, A.; Andres, R.; Herranz, J.; Bezares, S.; Caballero, R.; Alvarez, I.; Rojo, F. Mutational profile from circulating tumor DNA in triple negative breast cancer: Results from the prospective registry of unresectable locally advanced or metastatic breast cancer GEICAM/2014-03 (RegistEM). CANCER RESEARCH. 2021. DOI: 10.1158/1538-7445.SABCS20-PS5-22

  • López-Vega J.M.; Álvarez I.; Antón Torres, A.; Illarramendi J.J.; Llombart A.; Boni V.; García-Velloso M.J.; Martí-Climent J.M.; Pina L.; García-Foncillas J. Early imaging and molecular changes with neoadjuvant bevacizumab in stage ii/iii breast cancer. CANCERS. 2021. DOI: 10.3390/cancers13143511

  • Moreno, V.; Barretina-Ginesta, M.-P.; García-Donas, J.; Jayson, G.C.; Roxburgh, P.; Márquez Vázquez, R.; Michael, A.; Antón-Torres, A.; Brown, R.; Krige, D.; Champion, B.; Mcneish, I. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: A phase 1 clinical trial. JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2021. DOI: 10.1136/jitc-2021-003645

  • Donat-Vargas C.; Guerrero-Zotano Á.; Casas A.; Baena-Cañada J.M.; Lope V.; Antolín S.; Garcia-Saénz J.Á.; Bermejo B.; Muñoz M.; Ramos M.; de Juan A.; Jara Sánchez C.; Sánchez-Rovira P.; Antón Torres, A.; Brunet J.; Gavilá J.; Salvador J.; Arriola Arellano E.; Bezares S.; Fernández de Larrea-Baz N.; Pérez-Gómez B.; Martín M.; Pollán M. Trajectories of alcohol consumption during life and the risk of developing breast cancer. BRITISH JOURNAL OF CANCER. 2021. DOI: 10.1038/s41416-021-01492-w

  • Kahan, Z.; Gil-Gil, M.; Ruiz-Borrego, M.; Carrasco, E.; Ciruelos, E.; Muñoz, M.; Bermejo, B.; Margeli, M.; Antón, A.; Casas, M.; Csöszi, T.; Murillo, L.; Morales, S.; Calvo, L.; Lang, I.; Alba, E.; Haba-Rodriguez J. de La; Ramos, M.; Álvarez López, I.; Gal-Yam, E.; García-Palomo, A.; Álvarez, E.; González-Santiago, S.; Rodríguez, C. A.; Servitja, S.; Corsaro, M.; Rodrigálvarez, G.; Zielinski, C.; Martín, M. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study. EUROPEAN JOURNAL OF CANCER. 2021. DOI: 10.1016/j.ejca.2021.07.004

  • Fudio, S.; Tabernero, J.; Subbiah, V.; Chawla, S.P.; Moreno, V.; Longo, F.; Lopez, R.; Anton, A.; Trigo, J.M.; Shapiro, G.; Jeong, W.; Villalobos, V.M.; Lubomirov, R.; Fernandez-Teruel, C.; Alfaro, V.; Boni, V. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2021. DOI: 10.1007/s00280-020-04153-6

  • Garcia-Foncillas, J.; Anton-Torres, A.; Caballero-Martinez, F.; Campos, F.J.; Feyjoo, M.; de Liano, A.G.; Monge, D.; Camps, C. Patient Perspective on the Management of Cancer Pain in Spain. JOURNAL OF PATIENT EXPERIENCE. 2020. DOI: 10.1177/2374373520978872

  • Montemurro, F.; Delaloge, S.; Barrios, C.H.; Wuerstlein, R.; Anton, A.; Brain, E.; Hatschek, T.; Kelly, C.M.; Peña-Murillo, C.; Yilmaz, M.; Donica, M.; Ellis, P. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. ANNALS OF ONCOLOGY. 2020. DOI: 10.1016/j.annonc.2020.06.020

  • Ciruelos, E.M.; Montaño, A.; Rodríguez, C.A.; González-Flores, E.; Lluch, A.; Garrigós, L.; Quiroga, V.; Antón, A.; Malón, D.; Chacón, J.I.; Velasco, M.; Gonzalez-Cortijo, L.; Jolis, L.; Echarri, M.J.; Muñoz, M.; Pascual, T.; Amigo, Y.; Casas, M.; Carrasco, E.; Casas, A. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07). EUROPEAN JOURNAL OF CANCER CARE. 2020. DOI: 10.1111/ecc.13253

  • Lope, V.; Guerrero-Zotano, A.; Casas, A.; Baena-Cañada, J.M.; Bermejo, B.; Pérez-Gómez, B.; Criado-Navarro, I.; Antolín, S.; Sánchez-Rovira, P.; Ramos-Vázquez, M.; Antón, A.; Castelló, A.; García-Saénz, J.A.; Muñoz, M.; de Juan, A.; Andrés, R.; Llombart-Cussac, A.; Hernando, B.; Franquesa, R.M.; Caballero, R.; Priego-Capote, F.; Martín, M.; Pollán, M. Serum phospholipids fatty acids and breast cancer risk by pathological subtype. NUTRIENTS. 2020. DOI: 10.3390/nu12103132

  • Aranda, E.; Polo, E.; Camps, C.; Carrato, A.; Díaz-Rubio, E.; Guillem, V.; López, R.; Antón, A. Treatment patterns for metastatic colorectal cancer in Spain. CLINICAL AND TRANSLATIONAL ONCOLOGY. 2020. DOI: 10.1007/s12094-019-02279-5

  • Trigo, J.; Subbiah, V.; Besse, B.; Moreno, V.; López, R.; Sala, M.A.; Peters, S.; Ponce, S.; Fernández, C.; Alfaro, V.; Gómez, J.; Kahatt, C.; Zeaiter, A.; Zaman, K.; Boni, V.; Arrondeau, J.; Martínez, M.; Delord, J.P.; Awada, A.; Kristeleit, R.; Olmedo, M.E.; Wannesson, L.; Valdivia, J.; Rubio, M.J.; Anton, A.; Sarantopoulos, J.; Chawla, S.P.; Mosquera-Martinez, J.; D''arcangelo, M.; Santoro, A.; Villalobos, V.M.; Sands, J.; Paz-Ares, L. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. THE LANCET ONCOLOGY. 2020. DOI: 10.1016/S1470-2045(20)30068-1

  • Fernández de Larrea-Baz, N.; Pérez-Gómez, B.; Guerrero-Zotano, Á.; Casas, A.M.; Bermejo, B.; Baena-Cañada, J.M.; Antolin, S.; Sánchez-Rovira, P.; Ramos Vázquez, M.; Garcia-Sáenz, J.Á.; Antón, A.; Muñoz, M.; de Juan, A.; Jara, C.; Chacón, J.I.; Arcusa, A.; Gil-Gil, M.; Adrover, E.; Oltra, A.; Brunet, J.; González, S.; Bezares, S.; Lope, V.; Martín, M.; Pollán, M. Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study. SCIENTIFIC REPORTS (NATURE PUBLISHING GROUP). 2020. DOI: 10.1038/s41598-020-63637-w

  • Gavilá, J.; de la Haba, J.; Bermejo, B.; Rodríguez-Lescure, Á.; Antón, A.; Ciruelos, E.; Brunet, J.; Muñoz-Couselo, E.; Santisteban, M.; Rodríguez Sánchez, C.A.; Santaballa, A.; Sánchez Rovira, P.; García Sáenz, J. Á.; Ruiz-Borrego, M.; Guerrero-Zotano, A.L.; Huerta, M.; Cotes-Sanchís, A.; Lao Romera, J.; Aguirre, E.; Cortés, J.; Llombart-Cussac, A. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study. CLINICAL AND TRANSLATIONAL ONCOLOGY. 2020. DOI: 10.1007/s12094-019-02145-4

  • Subbiah, V.; Paz-Ares, L.; Besse, B.; Moreno, V.; Peters, S.; Sala, M.A.; López-Vilariño, J.A.; Fernández, C.; Kahatt, C.; Alfaro, V.; Siguero, M.; Zeaiter, A.; Zaman, K.; López, R.; Ponce, S.; Boni, V.; Arrondeau, J.; Delord, J.P.; Martínez, M.; Wannesson, L.; Antón, A.; Valdivia, J.; Awada, A.; Kristeleit, R.; Olmedo, M.E.; Rubio, M.J.; Sarantopoulos, J.; Chawla, S.P.; Mosquera-Martinez, J.; D’ Arcangelo, M.; Santoro, A.; Villalobos, V.M.; Sands, J.; Trigo, J. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. LUNG CANCER. 2020. DOI: 10.1016/j.lungcan.2020.10.003

  • Montemurro, F.; Ellis, P.; Anton, A.; Wuerstlein, R.; Delaloge, S.; Bonneterre, J.; Quenel-Tueux, N.; Linn, S.C.; Irahara, N.; Donica, M.; Lindegger, N.; Barrios, C.H. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1. EUROPEAN JOURNAL OF CANCER. 2019. DOI: 10.1016/j.ejca.2018.12.022

  • Ortega, V.; Antón, A.; Garau, I.; Afonso, N.; Calvo, L.; Fernández, Y.; Martínez-García, M.; Blanco, E.; Zamora, P.; García, M.; Illarramendi, J.J.; Rodríguez Sánchez, C.A.; Sampayo, M.; Aguirre, E.; Pérez-García, J.M.; Cortés, J.; Llombart-Cussac, A. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study. CLINICAL BREAST CANCER. 2019. DOI: 10.1016/j.clbc.2018.12.012

  • Lope, V.; Martín, M.; Castelló, A.; Ruiz, A.; Casas, A.M.; Baena-Cañada, J.M.; Antolín, S.; Ramos-Vázquez, M.; García-Sáenz, J.Á.; Muñoz, M.; Lluch, A.; de Juan-Ferré, A.; Jara, C.; Sánchez-Rovira, P.; Antón, A.; Chacón, J.I.; Arcusa, A.; Jimeno, M.ªa.; Bezares, S.; Vioque, J.; Carrasco, E.; Pérez-Gómez, B.; Pollán, M. Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study. SCIENTIFIC REPORTS (NATURE PUBLISHING GROUP). 2019. DOI: 10.1038/s41598-019-39346-4

  • Torregrosa, M.D.; Escudero, M.J.; Paredero, I.; Carrasco, E.; Bermejo, B.; Gavila, J.; García-Saenz., J; Santaella, A.; Martínez, P.; Llombart, A.; Andrés, R.; Batista, N.; Fernández, A.; Antón, A.; Seguí, M.; Gonzalez, S.; Ruiz, A. Evolution of older patients diagnosed with early breast cancer in Spain between 1998 and 2001 included in El Alamo III project. CLINICAL AND TRANSLATIONAL ONCOLOGY. 2019. DOI: 10.1007/s12094-019-02189-6

  • Ruíz-Borrego, Manuel; Guerrero-Zotano, Ángel; Bermejo, Begoña; Ramos, Manuel; Cruz, Josefina; Baena-Cañada, José Manuel; Cirauqui, Beatriz; Rodríguez-Lescure, Álvaro; Alba, Emilio; Martínez-Jáñez, Noelia; Muñoz, Montserrat; Antolín, Silvia; Álvarez, Isabel; del Barco, Sonia; Sevillano, Elena; Chacón, José Ignacio; Antón, Antonio; Escudero, María José; Ruiz, Victoria; Carrasco, Eva; Martín, Miguel; Geicam. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. BREAST CANCER RESEARCH AND TREATMENT. 2019. DOI: 10.1007/s10549-019-05296-8

  • Lopez, R.; Anton, A.; Aranda, E.; Carrato, A.; Constenla, M.; Cruz, J.J.; Diaz-Rubio, E.; Feyjoo, M.; Garcia-Foncillas, J.; Gascon, P.; Guillem, V.; Lugo, I.; Camps, C. Implementation of the quality training program in Spain. JOURNAL OF CLINICAL ONCOLOGY. 2019. DOI: 10.1200/JCO.2019.37.27_suppl.11

  • Camps Herrero, C.; Anton Torres, A.; Cruz-Hernández, J.J.; Carrato, A.; Constenla, M.; Díaz-Rubio, E.; Feyjoo Saus, M..; Garcia-Foncillas, J.; Gascón, P.; Guillem, V. Working towards a consensus on the oncological approach of breakthrough pain: A Delphi survey of Spanish experts. JOURNAL OF PAIN RESEARCH. 2019. DOI: 10.2147/JPR.S203903

  • López López, R.; Camps Herrero, C.; Khosravi-Shahi, P.; Guillem Porta, V.; Carrato Mena, A.; Garcia-Foncillas, J.; Cruz Hernández, J.J.; Gascón Vilaplana, P.; Antón Torres, A.; Diaz-Rubio, E.; Feyjoo Saus, M.; Aranda Aguilar, E. Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study. CLINICAL AND TRANSLATIONAL ONCOLOGY. 2018. DOI: 10.1007/s12094-017-1756-5

  • García-Foncillas, J.; Tabernero, J.; Élez, E.; Aranda, E.; Benavides, M.; Camps, C.; Jantus-Lewintre, E.; López, R.; Muinelo-Romay, L.; Montagut, C.; Antón, A.; López, G.; Díaz-Rubio, E.; Rojo, F.; Vivancos, A. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. BRITISH JOURNAL OF CANCER. 2018. DOI: 10.1038/s41416-018-0293-5

  • Gianni, L.; Mansutti, M.; Anton, A.; Calvo, L.; Bisagni, G.; Bermejo, B.; Semiglazov, V.; Thill, M.; Chacon, J.I.; Chan, A.; Morales, S.; Alvarez, I.; Plazaola, A.; Zambetti, M.; Redfern, A.D.; Dittrich, C.; Dent, R.A.; Magazzu, D.; de Fato, R.; Valagussa, P.; Tusquets, I. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial A Randomized Phase 3 Clinical Trial. JAMA ONCOLOGY. 2018. DOI: 10.1001/jamaoncol.2017.4612

  • Esteban, I.; Vilaró, M.; Adrover, E.; Angulo, A.; Carrasco, E.; Gadea, N.; Sánchez, A.; Ocaña, T.; Llort, G.; Jover, R.; Cubiella, J.; Servitja, S.; Herráiz, M.; Cid, L.; Martínez, S.; Oruezábal-Moreno, M.J.; Garau, I.; Khorrami, S.; Herreros-De-Tejada, A.; Morales, R.; Cano, J.M.; Serrano, R.; López-Ceballos, M.H.; González-Santiago, S.; Juan-Fita, M.J.; Alonso-Cerezo, C.; Casas, A.; Graña, B.; Teulé, A.; Alba, E.; Antón, A.; Guillén-Ponce, C.; Sánchez-Heras, A.B.; Alés-Martínez, J.E.; Brunet, J.; Balaguer, F.; Balmaña, J. Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain. PSYCHO-ONCOLOGY. 2018. DOI: 10.1002/pon.4686

  • Pajares Bernad, I.; Martínez Trufero, J.; Calera Urquizu, L.; Pazo Cid, R.A.; Cebollero de Miguel, A.; Agustin, M.J.; Lanzuela, M.; Anton, A. Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors. CLINICAL AND TRANSLATIONAL ONCOLOGY. 2017. DOI: 10.1007/s12094-016-1604-z

  • Márquez-Rodas, I.; Pollán, M.; Escudero, M.J.; Ruiz, A.; Martín, M.; Santaballa, A.; Martínez del Prado, P.; Batista, N.; Andrés, R.; Antón, A.; Llombart, A.; Fernandez Aramburu, A.; Adrover, E.; González, S.; Seguí, M.A.; Calvo, L.; Lizón, J.; Rodríguez Lescure, Á.; Ramón y Cajal, T.; Llort, G.; Jara, C.; Carrasco, E.; López-Tarruella, S. Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study. PLOS ONE. 2017. DOI: 10.1371/journal.pone.0184181

  • Alsina, M.; Rivera, F.; Ramos, F.J.; Galán, M.; López, R.; García-Alfonso, P.; Alés-Martinez, J.E.; Queralt, B.; Antón, A.; Carrato, A.; Grávalos, C.; Méndez-Vidal, M.J.; López, C.; de Mena, I.R.; Tabernero, J.; Giralt, J.; Aranda, E.; On, Behalf, Of, The, Spanish, Cooperative, Group, For, The, Treatment, Of, Digestive, Tumors, (ttd), And, Grupo, De, Investigacion, Clinica, En, Oncologia, Radioterapica, (gicor). Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. TARGETED ONCOLOGY. 2017. DOI: 10.1007/s11523-017-0544-z

  • Alsina, M.; Rivera, F.; Ramos, F.J.; Galán, M.; López, R.; García-Alfonso, P.; Alés-Martinez, J.E.; Queralt, B.; Antón, A.; Carrato, A.; Grávalos, C.; Méndez-Vidal, M.J.; López, C.; de Mena, I.R.; Tabernero, J.; Giralt, J.; Aranda, E.; On, Behalf, Of, The, Spanish, Cooperative, Group, For, The, Treatment, Of, Digestive, Tumors, (ttd), And, Grupo, De, Investigacion, Clinica, En, Oncologia, Radioterapica, (gicor). Cetuximab/TPF/radiotherapy in oesophageal cancer. TARGETED ONCOLOGY. 2017. DOI: 10.1007/s11523-017-0536-z

  • Lope, V.; Martín, M.; Castelló, A.; Casla, S.; Ruiz, A.; Baena-Cañada, J. M.; Casas, A. M.; Calvo, L.; Bermejo, B.; Muñoz, M.; Ramos, M.; de Juan-Ferré, A.; Jara, C.; Antón, A.; Jimeno, M. Á.; Lluch, A.; Antolín, S.; García-Sáenz, J. Á.; Estévez, P.; Arriola-Arellano, E.; Gavilá, J.; Pérez-Gómez, B.; Carrasco, E.; Pollán, M. Physical activity and breast cancer risk by pathological subtype. GYNECOLOGIC ONCOLOGY. 2017. DOI: 10.1016/j.ygyno.2016.12.014

  • Martín, M.; Chacón, J.I.; Antón, A.; Plazaola, A.; García-Martínez, E.; Seguí, M.A.; Sánchez-Rovira, P.; Palacios, J.; Calvo, L.; Esteban, C.; Espinosa, E.; Barnadas, A.; Batista, N.; Guerrero, A.; Muñoz, M.; Romio, E.; Rodríguez-Martín, C.; Caballero, R.; Casas, M.I.; Rojo, F.; Carrasco, E.; Antolín, S. Neoadjuvant therapy with weekly nanoparticle albumin-bound paclitaxel for luminal early breast cancer patients: Results from the nabrax study (GEICAM/2011-02), a multicenter, non-randomized, phase ii trial, with a companion biomarker analysis. ONCOLOGIST. 2017. DOI: 10.1634/theoncologist.2017-0052

  • González, A.; Lluch, A.; Aba, E.; Albanell, J.; Antón, A.; Álvarez, I.; Ayala, F.; Barnadas, A.; Calvo, L.; Ciruelos, E.; Cortés, J.; De, La Haba; López-Vega, J. M.; Martínez, E.; Muñoz, M.; Peláez, I.; Redondo, A.; Rodríguez, Á.; Rodríguez, C. A.; Ruíz, A.; Llombart, A. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM). CLINICAL AND TRANSLATIONAL ONCOLOGY. 2017. DOI: 10.1007/s12094-016-1571-4

  • Moran, S.; Martínez-Cardús, A.; Sayols, S.; Musulén, E.; Balañá, C.; Estival-Gonzalez, A.; Moutinho, C.; Heyn, H.; Diaz-Lagares, A.; de Moura, M. C.; Stella, G. M.; Comoglio, P. M.; Ruiz-Miró, M.; Matias-Guiu, X.; Pazo-Cid, R.; Antón, A.; Lopez-Lopez, R.; Soler, G.; Longo, F.; Guerra, I.; Fernandez, S.; Assenov, Y.; Plass, C.; Morales, R.; Carles, J.; Bowtell, D.; Mileshkin, L.; Sia, D.; Tothill, R.; Tabernero, J.; Llovet, J. M.; Esteller, M. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. THE LANCET ONCOLOGY. 2016. DOI: 10.1016/S1470-2045(16)30297-2

  • Alba, E.; Lluch, A.; Ribelles, N.; Anton-Torres, A.; Sanchez-Rovira, P.; Albanell, J.; Calvo, L.; García-Asenjo, J.A.; Palacios, J.; Chacon, J.I.; Ruiz, A.; de la Haba-Rodriguez J.; Segui-Palmer, M.A.; Cirauqui, B.; Margeli, M.; Plazaola, A.; Barnadas, A.; Casas, M.; Caballero, R.; Carrasco, E.; Rojo, F. High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. ONCOLOGIST. 2016. DOI: 10.1634/theoncologist.2015-0312

  • Camps, C.; Albanell, J.; Antón, A.; Aranda, E.; Carrato, A.; Cassinello, J.; Castellano, D.; Cruz, J. J.; Garrido, P.; Guillem, V.; Grávalos, C.; López, G.; Llorente, C.; Lorenzo, A.; Lluch, A.; Ignacio, E.; Díaz-Rubio, E. Quality indicators to assure and improve cancer care in Spain using the delphi technique. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. 2016. DOI: 10.6004/jnccn.2016.0063

  • Cebollero de Miguel, A.; Pazo Cid, R.; Martinez Trufero, J.; Pajares Bernad, I.; Calera Urquizu, L.; Hernando Cubero, J.; Antón Torres, A. Gene expression profiling and its use in adenocarcinomas of unknown primary origin: A case report. ONCOLOGY LETTERS. 2015. DOI: 10.3892/ol.2015.3572

  • Antolín-Novoa, S.; Blanco-Campanario, E.; Antón, A.; Gallegos-Sancho, M.; Pérez-Carrión, R.; Peláez, I.; Galán-Brotons, A.; de la Cruz-Merino, L.; Murías-Rosales, A. Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice. CLINICAL AND TRANSLATIONAL ONCOLOGY. 2015. DOI: 10.1007/s12094-015-1316-9

  • Martín, M.;Loibl, S.;Von Minckwitz, G.;Morales, S.;Martinez, N.;Guerrero, A.;Anton, A.;Aktas, B.;Schoenegg, W.;Muñoz, M.;Garcia-Saenz, J.;Gil, M.;Ramos, M.;Margeli, M.;Carrasco, E.;Liedtke, C.;Wachsmann, G.;Mehta, K.;Haba, de la. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer:The Letrozole/Fulvestrant and Avastin (LEA) study. JOURNAL OF CLINICAL ONCOLOGY. 2015. DOI: 10.1200/JCO.2014.57.2388

  • Castelló, A.; Martín, M.; Ruiz, A.; Casas, A.M.; Baena-Cañada, J.M.; Lope, V.; Antolín, S.; Sánchez, P.; Ramos, M.; Antón, A.; Muñoz, M.; Bermejo, B.; de Juan-Ferré, A.; Jara, C.; Chacón, J.I.; Jimeno, M.A.; Rosado, P.; Díaz, E.; Guillem, V.; Lluch, A.; Carrasco, E.; Pérez-Gómez, B.; Vioque, J.; Pollán, M. Lower breast cancer risk among women following the World Cancer Research Fund and American Institute for Cancer Research lifestyle recommendations: Epigeicam case-control study. PLOS ONE. 2015. DOI: 10.1371/journal.pone.0126096

  • Barnadas,A.; Manso,L.; De,La Piedra; Meseguer,C.; Crespo,C.; Gómez,P.; Calvo,L.; Martinez,P.; Ruiz-Borrego,M.; Perelló,A.; Antón,A.; Codes,M.; Margelí,M.; Murias,A.; Salvador,J.; Seguí,M. T.; de Juan,A.; Gavilá,J.; Luque,M.; Pérez,D.; Zamora,P.; Arizcuma,A.; Chacón,J. I.; Heras,L.; Martin-Fernández,M.; Mahillo-Fernández,I.; Tusquets,I. Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study). BONE. 2014. DOI: 10.1016/j.bone.2014.07.036

  • de Dueñas, E. M.; Hernández, A. L.; Zotano, A. G.; Carrión, R. M. P.; López-Muñiz, J. I. C.; Novoa, S. A.; Rodríguez, A. L.; Fidalgo, J. A. P.; Lozano, J. F.; Gasión, O. B.; Carrascal, E. C.; Capilla, A. H.; López-Barajas, I. B.; Mateu, M. M.; De, Ceballos Reyna; Ferrando, A. O.; Jañez, N. M.; Ballerini, V. C.; Antón Torres, A.; Catalán, G.; Sáenz, J. A. G.; Menjón, S.; González-Angulo, A. M. Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: Results from the GEICAM 2009-03 ConvertHER study. BREAST CANCER RESEARCH AND TREATMENT. 2014. DOI: 10.1007/s10549-013-2825-2

  • Hernando-Cubero, J.; Alonso-Orduña, V.; Hernandez-Garcia, A.; de Miguel, A. C.; Alvarez-Garcia, N.; Anton-Torres, A. Brain metastasis in basaloid undifferentiated anal carcinoma: A case report. ONCOLOGY LETTERS. 2014. DOI: 10.3892/ol.2014.1845

  • Escobar,Y.; Mañas,A.; Juliá,J.; Gálvez,R.; Zaragozá,F.; Margarit,C.; López,R.; Casas,A.; Antón,A.; Cruz,J. J. Optimal management of breakthrough cancer pain (BCP). CLINICAL AND TRANSLATIONAL ONCOLOGY. 2013. DOI: 10.1007/s12094-012-0981-1

  • Carrato,A.; Gómez,A.; Escudero,P.; Chaves,M.; Rivera,F.; Marcuello,E.; González,E.; Grávalos,C.; Constenla,M.; Manzano,J. L.; Losa,F.; Maurel,J.; Dueñas,R.; Massuti,B.; Gallego,J.; Aparicio,J.; Antón,A.; Aranda,E. Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. CLINICAL AND TRANSLATIONAL ONCOLOGY. 2013. DOI: 10.1007/s12094-012-0993-x

  • Zaragozá, F.; Julià, J.; Margarit, C.; López, R.; Anton, A.; Escobar, Y.; Casas, A.; Cruz, J. J.; Galvez, R.; Mañas, A. Relationship between the pharmacokinetic properties and efficacy of fentanyl pectin nasal spray in breakthrough cancer pain. ATENCIÓN FARMACÉUTICA. 2013

  • Pazo Cid, R. A.;Antón, A. Advanced HER2-positive gastric cancer: Current and future targeted therapies. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2013. DOI: 10.1016/j.critrevonc.2012.08.008

  • Sánchez-Rovira,P.;Seguí,M. A.;Llombart,A.;Aranda,E.;Antón,A.;Sánchez,A.;Lomas,M.;Jaén,A.;Fernández,M.;Porras,I.;Dalmau,E.;Morales,S.;Haba,de la. Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: Biomarkers and pathologic response. CLINICAL AND TRANSLATIONAL ONCOLOGY. 2013. DOI: 10.1007/s12094-013-1006-4

  • Pajares, B.; Pollán, M.; Martín, M.; Mackey, J. R.; Lluch, A.; Gavila, J.; Vogel, C.; Ruiz-Borrego, M.; Calvo, L.; Pienkowski, T.; Rodríguez-Lescure, T.; Seguí, M. A.; Tredan, O.; Antón, A.; Ramos, M.; Cámara, M. D. C.; Rodríguez-Martín, C.; Carrasco, E.; Alba, E. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: A pooled analysis. BREAST CANCER RESEARCH. 2013. DOI: 10.1186/bcr3572

  • Pazo Cid, R.A; Álvarez Alejandro, M.; Cebollero de Miguel, A.; Agustín, M.J.; Martinez-Lostao, L.; Anel Bernal, A.; Pérez Gracia, J.L.; Antón Torres, A. Apoptosis, cáncer & Co. REVISTA INTERNACIONAL DE GRUPOS DE INVESTIGACIÓN EN ONCOLOGÍA. 2012

  • Anton, A.;Lluch, A.;Casado, A.;Provencio, M.;Muñoz, M.;Lao, J.;Bermejo, B.;Paules, A. B.;Gayo, J. ;Martin, M. Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer. ANTICANCER RESEARCH. 2010

  • Bellmunt, J.;Maroto-Rey, P.;Trigo, J. M.;Carles, J.;Guillem, V.;Lopez-Martin, J. A.;Anton-Torres, A. ;Urruticoechea, L. A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. CLINICAL AND TRANSLATIONAL ONCOLOGY. 2010. DOI: 10.1007/s12094-010-0544-2

  • Pazocid, R. A.;Alvarez Alejandro, M.;Yus, C.;Remon, L.;Gil, I.;Madani, J.;Cebollero de Miguel, A.;Lao Romera, J.;Lecumberri Biurrum, M. J. ;Anton, A. Clinical outcome of advanced gastric cancer (GC) patients (pts) by human epidermal growth factor receptor 2 (HER2) status when treated before the trastuzumab era. ANNALS OF ONCOLOGY. 2010

  • Puente, J.; Lopez-Tarruella, S.; Ruiz, A.; Lluch, A.; Pastor, M.; Alba, E.; de la Haba, J.; Ramos, M.; Cirera, L.; Anton, A.; Llombart, A.; Plazaola, A.; Fernandez-Aramburo, A.; Sastre, J.; Diaz-Rubio, E. ; Martin, M. Practical prognostic index for patients with metastatic recurrent breast cancer: Retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. BREAST CANCER RESEARCH AND TREATMENT. 2010. DOI: 10.1007/s10549-009-0687-4

  • Lanzuela, M.;Pazo Cid, R. A.;Lao, J.;Fuentes, J.;Sarria, L.;Horndler, C.;Ubieto, M. A.;Puertolas, T.;Calderero, V. ;Anton, A. Early response evaluation of sorafenib (SFB) therapy: Use of computed fluorodeoxiglucose positron emission tomography (PET-CT) in advanced hepatocellular carcinoma (HCC). JOURNAL OF CLINICAL ONCOLOGY. 2010

  • Llombart, A.;Mayordomo, J. I.;Anton, A.;Santaballa, A.;Ruiz, A. ;Rodriguez-Lescure, A. Long term cardiac safety of pegylated liposomal doxorubicin (PLD) in patients with breast cancer (BC) previously treated with conventional anthracyclines. ANNALS OF ONCOLOGY. 2010

  • Martin, M.;Segui, M. A.;Anton, A.;Ruiz, A.;Ramos, M.;Adrover, E.;Aranda, I.;Rodriguez-Lescure, A.;Grosse, R.;Calvo, L.;Barnadas, A.;Isla, D.;Martinez del Prado, P.;Borrego, M. R.;Zaluski, J.;Arcusa, A.;Munoz, M.;Lopez Vega, J. M.;Mel, J. R.;Munarriz, B.;Llorca, C.;Jara, C.;Alba, E.;Florian, J.;Li, J.;Lopez Garcia-Asenjo, J. Adjuvant docetaxel for high-risk, node-negative breast cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2010

  • Pazo Cid, R.;Calderero, V.;Puertolas, T.;Fuentes, J.;Lao, J.;Lecumberri, M.;Gil, I.;Madani, J.;Alvarex Alejandro, M.;Lanzuela, M.;Alonso, V.;Herrero, A.;Martinez-Trufero, J.;Artal, A.;Anton, A. Role of Positron Emission Tomography (Pet) Imaging in the Evaluation of Response to Sorafenib Treatment in Advanced Hepatocellular Carcinoma (Hcc). ANNALS OF ONCOLOGY. 2009

  • Pazo Cid, R.;Lao Romera, J.;Lanzuela, M.;Fuentes, J.;Barrao, E.;Sarria, L.;Hordnler, C.;Ubieto, M. A.;Serrablo, A.;Anton, A. Evaluation of Response to Sorafenib Treatment in Advanced Hepatocellular Carcinoma (HCC): Role of Positron Emission Tomography (PET) Imaging. EJC SUPPLEMENTS. 2009

  • Pazo Cid, R.;Lao Romera, J.;Lanzuela, M.;Gil, I.;Godoy, A.;Fernandez-Mosteirin, N.;Madani, J.;Lecumberri, M. J.;Alvarez Alejandro, M.;Anton, A. Peripheral Blood Lymphocite Populations in Advanced Gastric Cancer Patients have Predictive and Prognostic Value. EJC SUPPLEMENTS. 2009

  • Pazo-Cid, R.;Godoy, A.;Romera, J. L.;Fernandez-Mosteirin, N.;Puertolas, T.;Calderero, V.;Garcia-Foncillas, R.;Lucia, J. F.;Lecumberri, M. J.;Anton, A. Von Willebrand Factor and Fibrinogen Levels Predict Outcome in Advanced Gastric Cancer Patients. EJC SUPPLEMENTS. 2009

  • Rivera, F.;Galan, M.;Tabernero, J.;Cervantes, A.;Vega-Villegas, M.;Gallego, J.;Laquente, B.;Rodriguez, E.;Carrato, A.;Escudero, P.;Massuti, B.;Alonso-Orduna, V.;Cardenal, A.;Saenz, A.;Giralt, J.;Yuste, A. L.;Anton, A.;Aranda, E. Phase II Trial of Preoperative Irinotecan-Cisplatin Followed by Concurrent Irinotecan-Cisplatin and Radiotherapy for Resectable Locally Advanced Gastric and Esophagogastric Junction Adenocarcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2009

  • Calderero Aragon, V;Gregorio Ariza, M.A.De;Pazo Cid, R;Puertolas Hernandez, T;Lostale Latorre, F;Artal Cortes, A;Anton Torres, A. Role of Low Molecular Weight Heparins in Prophylaxis of Thromboembolic Events on Oncological Patients with Indwelling Central Venous Catheter. MEDICINA CLINICA. 2009

  • Chan, S.;Romieu, G.;Huober, J.;Delozier, T.;Tubiana-Hulin, M.;Schneeweiss, A.;Lluch, A.;Llombart, A.;Du Bois, A.;Kreienberg, R.;Mayordomo, J. I.;Anton, A.;Harrison, M.;Jones, A.;Carrasco, E.;Vaury, A. T.;Frimodt-Moller, B.;Fumoleau, P. Phase III Study of Gemcitabine Plus Docetaxel Compared with Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients with Metastatic Breast Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2009

  • Abad, A.;Massuti, B.;Anton, A.;Vega, M. E.;Yuste, A. L.;Marcuello, E.;Manzano, J. L.;Alonso, V.;Carrato, A.;Martinez-Villacampa, M.;Tabernero, J.;Aranda, E.;Rivera, F.;Diaz-Rubio, E.;Spanish Cooperative Grp Digestive. Colorectal Cancer Metastasis Resectability After Treatment with the Combination of Oxaliplatin, Irinotecan and 5-Fluorouracil. Final Results of a Phase II Study. ACTA ONCOLOGICA. 2008

  • Martin, M.;Rodriguez-Lescure, A.;Ruiz, A.;Alba, E.;Calvo, L.;Ruiz-Borrego, M.;Munarriz, B.;Rodriguez, C. A.;Crespo, C.;de Alava, E.;Lopez Garcia-Asenjo, J. A.;Dolores Guitian, M.;Almenar, S.;Fernando Gonzalez-Palacios, J.;Vera, F.;Palacios, J.;Ramos, M.;Gracia Marco, J. M.;Lluch, A.;Alvarez, I.;Angel Segui, M.;Ignacio Mayordomo, J.;Anton, A.;Manuel Baena, J.;Plazaola, A.;Modolell, A.;Pelegri, A.;Ramon Mel, J.;Aranda, E.;Adrover, E.;Valero Alvarez, J.;Garcia Puche, J. L.;Sanchez-Rovira, P.;Gonzalez, S.;Manuel Lopez-Vega, J.;Geicam 9906 Study Investigators. Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone Or Followed by Paclitaxel for Early Breast Cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2008

  • Martin, M.;Lluch, A.;Segui, M. A.;Ruiz, A.;Ramos, M.;Adrover, E.;Rodriguez-Lescure, A.;Grosse, R.;Calvo, L.;Anton, A. Tac Versus Fac as Adjuvant Chemotherapy for High-Risk Node-Negative Breast Cancer: Results of the Geicam 9805 Trial. ANNALS OF ONCOLOGY. 2008

  • Miramar, M. D.;Calvo, M. T.;Rodriguez, A.;Anton, A.;Lorente, F.;Barrio, E.;Herrero, A.;Burriel, J.;de Jalon, A. G. Genetic Analysis of BRCA1 and BRCA2 in breast/ovarian Cancer Families from Aragon (Spain): Two Novel Truncating Mutations and a Large Genomic Deletion in BRCA1. BREAST CANCER RESEARCH AND TREATMENT. 2008. DOI: 10.1007/s10549-007-9868-1

  • Hernandez-Vargas, H;Rodriguez-Pinilia, S;Julian-Tendero, M;Sanchez-Rovira, P;Cuevas, C;Anton, A;Rios, M.Jesus;Palacios, J;Moreno-Bueno, G. Gene Expression Profiling of Breast Cancer Cells in Response to Gemcitabine: NF-Kappa B Pathway Activation as a Potential Mechanism of Resistance. BREAST CANCER RESEARCH AND TREATMENT. 2007. DOI: 10.1007/s10549-006-9322-9

  • Sanchez, C. J.; Ruiz, A.; Martin, M.; Anton, A.; Munarriz, B.; Plazaola, A.; Schneider, J.; del Prado, P. M.; Alba, E.; Fernandez-Aramburo, A. Influence of Timing of Initiation of Adjuvant Chemotherapy Over Survival in Breast Cancer: A Negative Outcome Study by the Spanish Breast Cancer Research Group (GEICAM). BREAST CANCER RESEARCH AND TREATMENT. 2007. DOI: 10.1007/s10549-006-9282-0

Conference presentations

  • Subbiah, V.; Paz-Ares, L.; Besse, B.; Zaman, K.; Sala, M.A.; Lopez-Vilarino, J.A.; Fernandez, C.; Kahatt, C.; Siguero, M.; Zeaiter, A.; Arrondeau, J.; Delord, J.P.; Martinez, M.; Anton, A.; Trigo, J.M.; Wannesson, L. Activity of Lurbinectedin in Second-line SCLC Patients Who Are Candidates for Platinum Rechallenge. JOURNAL OF THORACIC ONCOLOGY. 2021. DOI: 10.1016/j.jtho.2020.10.058

  • Subbiah, V.; Paz-Ares, L.; Besse, B.; Moreno, V.; Peters, S.; Sala, M.A.; Lopez-Vilarino, J.A.; Fernandez, C.; Kahatt, C.; Zeaiter, A.; Zaman, K.; Delord, J.P.; Martinez, M.; Anton, A.; Awada, A.; Kristeleit, R.; Olmedo, M.E.; Rubio, M.J.; Sarantopoulos, J.; D''arcangelo, M.; Santoro, A.; Trigo, J.M.; Sands, J. Phase 2 Basket Trial of Lurbinectedin in Second-line SCLC: Characteristics and Outcomes in Treatment Responders. JOURNAL OF THORACIC ONCOLOGY. 2021. DOI: 10.1016/j.jtho.2020.10.056

  • Sands, J.; Paz-Ares, L.; Besse, B.; Peters, S.; Sala, M.A.; Lopez-Vilarino, J.A.; Fernandez, C.; Kahatt, C.; Zeaiter, A.; Nieto, A.; Siguero, M.; Zaman, K.; Arrondeau, J.; Delord, J.P.; Martinez, M.; Anton, A.; Awada, A.; Kristeleit, R.; Olmedo, M.E.; Rubio, M.J.; Sarantopoulos, J.; Mosquera-Martinez, J.; D''arcangelo, M.; Santoro, A.; Trigo, J.M.; Subbiah, V.; Arrondeau, J. Phase 2 Basket Trial of Lurbinectedin in Small-Cell Lung Cancer (SCLC): Analysis of Efficacy by Baseline Characteristics. JOURNAL OF THORACIC ONCOLOGY. 2021. DOI: 10.1016/j.jtho.2020.10.057

  • Guerrero-Zotano, A.; Zielinski, C.; Gil-Gil, M.; Ruiz-Borrego, M.; Ciruelos, E.M.; Munoz, M.; Bermejo, B.; Margeli, M.; Anton, A.; Csoszi, T.; Garcia-Palomo, A.; Santaballa, A.; Alonso, J.L.; Fernandez, A.; Corsaro, M.; Herranz, J.; Lopez, P.; Caballero, R.; Thallinger, C.; Martin, M. Plk1 expression & efficacy of palbociclib in advanced hormonal receptor-positive breast cancer patients from PEARL study (GEICAM 2012-03). CANCER RESEARCH. 2021. DOI: 10.1158/1538-7445.SABCS20-PS2-01

  • Alvarez, I.; Guerrero, A.; Lopez-Tarruella, S.; Martinez, P.; Mori, M.; Falo, C.; Antolin, S.; Rodriguez, C.A.; Margeli, M.; Garau, I.; Tibau, A.; Moreno, D.; Cruz, J.; Echarri, M.J.; Anton, A.; Rodriguez-Lescure, A.; Escudero, M.J.; Bezares, S.; Rojo, F.; Jara, C. Characteristics of HR+/HER2-patients with recurrent disease by HER2 expression from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM). CANCER RESEARCH. 2021. DOI: 10.1158/1538-7445.SABCS20-PS7-24

  • Pollan, Marina; Lope, Virginia; Guerrero-Zotano, Angel; Casas, Ana; Baena-Cañada, José Manuel; Bermejo, Begoña; Perez-Gomez, Beatriz; Sanchez-Rovira, Pedro; Ramos Vazquez, Manuel; Anton, Antonio; Garcia-Saenz, Jose Angel; Munoz, Montserrat; de Juan, Ana; Andres, Raquel; Llombart Cussac, Antonio; Hernando, Blanca; Franquesa, Rosa María; Caballero, Rosalia; Martin, Miguel; Priego, Feliciano. Serum phospholipids fatty acids and breast cancer risk by pathological subtype: EpiGEICAM study. JOURNAL OF CLINICAL ONCOLOGY. 2020

  • Martin, Miguel; Zielinski, Christoph; Ruiz-Borrego, Manuel; Carrasco, Eva Maria; Ciruelos, Eva; Muñoz, Montserrat; Bermejo, Begoña; Vila, Mireia Margeli; Turner, Nicholas C.; Casas, Maribel; Anton, Antonio; Murillo Jaso, Laura; Lang, Istvan; Bartlett, Cynthia Huang; Koehler, Maria; Martin, Nuria; Corsaro, Massimo; Swift, Claire; Nisenbaum, Bella; Gil Gil, Miguel J. Prognostic and predictive value of ESR1 mutations in postmenopausal metastatic breast cancer (MBC) patients (pts) resistant to aromatase inhibitors (AI), treated with palbociclib (PAL) in combination with endocrine therapy (ET) or capecitabine (CAP) in the PEARL study. JOURNAL OF CLINICAL ONCOLOGY. 2020

  • Bianchini, Giampaolo; Smart, Chanel; Mansutti, Mauro; Lück, Hans-Joachim; Zambelli, Stefania; Olier, Clara; Anton, Antonio; Bisagni, Giancarlo; Merlini, Laura; Murillo, Serafin Morales; Calvo Martínez, Lourdes; Chacon, Jose Ignacio; Semiglazov, Vladimir; Thill, Marc; Chan, Arlene; Tusquets, Ignasi; Licata, Luca; Valagussa, Pinuccia; Viale, Giuseppe; Gianni, Luca. Modulation by treatment of tumor infiltrating lymphocytes (TILs) and PDL1 expression in triple-negative breast cancer in the ETNA trial. JOURNAL OF CLINICAL ONCOLOGY. 2020

  • Subbiah, V.; Paz-Ares, L.; Besse, B.; Moreno, V.; Zaman, K.; Gonzalez, M.A.S.; Lopez-Vilarino, J.A.; Fernandez, C.M.; Kahatt, C.; Siguero, M.; Zeaiter, A.; Lopez, R.L.; Aix, S.P.; Boni, V.; Arrondeau, J.; Delord, J.P.; Martinez-Aguillo, M.; de Nicola, L.W.; Anton Torres, A.; Perez, J.M.T. Activity of lurbinectedin in second-line SCLC patients candidates for platinum re-challenge. ANNALS OF ONCOLOGY. 2020. DOI: 10.1016/j.annonc.2020.08.1545

  • Garcia-Foncillas, J.; Anton, A.; Martinez, F.C.; Feijoo, M.; de Liano, A.G.; Porta, V.G.; Monge, D.; Campos Lucas, F.J.; Camps Herrero, C.J.C. Pain in cancer: The patient experience in Spain. ANNALS OF ONCOLOGY. 2020. DOI: 10.1016/j.annonc.2020.08.1516

  • Bianchini, G.; Huang, C.S.; Egle, D.; Bermejo, B.; Zamagni, C.; Thill, M.; Anton, A.; Zambelli, S.; Russo, S.; Ciruelos, E.M.; Greil, R.; Semiglazov, V.; Colleoni, M.A.; Kelly, C.M.; Mariani, G.; del Mastro, L.; Smart, C.; Valagussa, P.; Viale, G.; Gianni, L. Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial. ANNALS OF ONCOLOGY. 2020. DOI: 10.1016/j.annonc.2020.08.2241

  • Kahan, Z.; Gil-Gil, M.; Ruiz-Borrego, M.; Carrasco, E.M.; Ciruelos, E.M.; Munoz, M.; de las Heras, B.B.; Vila, M.M.; Anton, A.; Casas, M.; Calvo, L.; de la Haba, J.; Ramos, M.; Alvarez-Lopez, I.; Gal-Yam, E.; Gautier, E.; Corsaro, M.; Rodrigalvarez, G.; Zielinski, C.; Jimenez, M.M. Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study. ANNALS OF ONCOLOGY. 2020. DOI: 10.1016/j.annonc.2020.03.244

  • Zambelli, S.; Smart, C.; Bianchini, G.; Sassi, I.; Mansutti, M.; Anton, A.; Calvo, L.; Bisagni, G.; Bermejo, B.; Ugge, M.; Galbardi, B.; Semiglazov, V.; Thill, M.; Chacon, J.I.; Chan, A.; Murillo, S.M.; Alvarez, I.; Lahuerta, A.; Zucchinelli, P.; Doglioni, C.; Valagussa, P.; Tusquets, I.; Gianni, L.; Bernardi, R. Prognostic and predictive value of PML in the ETNA study and the TCGA. CANCER RESEARCH. 2020. DOI: 10.1158/1538-7445.SABCS19-P5-06-21

  • Perez-Garcia, J.M.; Salgado, A.C.; Miranda, E.L.; Anton, A.; Rovira, P.S.; Fernandez, B.C.; Gonzalez, A.L.; Garau, I.; Martinez, A.; Aparicio, M.C.; del Barco, S.; Sampayo, M.; Riva, F.; Malfettone, A.; Llombart-Cussac, A.; Cortes, J. A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT study). CANCER RESEARCH. 2020. DOI: 10.1158/1538-7445.SABCS19-OT2-09-01

  • Gianni, L.; Huang, C.S.; Egle, D.; Bermejo, B.; Zamagni, C.; Thill, M.; Anton, A.; Zambelli, S.; Bianchini, G.; Russo, S.; Ciruelos, E.; Greil, R.; Semiglazov, V.; Colleoni, M.; Kelly, C.; Mariani, G.; del Mastro, L.; Maffeis, I.; Valagussa, P.; Viale, G. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. CANCER RESEARCH. 2020. DOI: 10.1158/1538-7445.SABCS19-GS3-04

  • de la Haba, J.; Morales-Ruiz, T.; Garcia-Alfonso, P.; Lorenzo, J.P.; Calvo, L.; Anton, A.; Marquez, R.; Sanchez-Rovira, P.; Santaballa, A.; Ciruelos, E.; Garcia-Ortiz, M.V.; Roldan-Arjona, T.; Herranz, J.; Chiesa, M.; Caballero, R.; Gallego, J.; Rodriguez-Lescure, A. Identification of a specific epigenetic signature in patients showing secondary hypertension upon anti-VEGF treatment from the GEICAM/2011-04 (BRECOL) study. CANCER RESEARCH. 2020. DOI: 10.1158/1538-7445.SABCS19-P4-10-28

  • Bianchini, G.; Smart, C.; Mansutti, M.; Anton, A.; Licata, L.; Sassi, I.; Calvo, L.; Bisagni, G.; Bermejo, B.; Semiglazov, V.; Thill, M.; Chacon, J.I.; Chan, A.; Murillo, S.M.; Alvarez, I.; Lahuerta, A.; Zucchinelli, P.; Doglioni, C.; Viale, G.; Valagussa, P.; Tusquet, I.; Gianni, L. Clinical implication of tumor infiltrating lymphocytes (TILs) in the ETNA study. CANCER RESEARCH. 2020. DOI: 10.1158/1538-7445.SABCS19-PD5-05

  • Ocana, A.; Chacon, J.M.; Calvo, L.; Anton, A.; Mansutti, M.; Alba, E.; Lluch, A.; Lahuerta, A.; Bisagni, G.; Bermejo, B.; Semiglazov, V.; Thill, M.; Chan, A.; Morales, S.; Albanell, J.; Herranz, J.; Bes, I.T.T.; Valagussa, P.; Chiesa, M.; Gianni, L. Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT). ANNALS OF ONCOLOGY. 2019. DOI: 10.1093/annonc/mdz240.094

  • Salvador, J.; Ciruelos, E.M.; Jimenez-Rodriguez, B.; de la Cruz, L.; Vazquez, R.V.; de Toro, R.; Anton, A.; Moreno, F.; Alvarez, I.; Quiroga, V.; de la Haba, J.; Gonzalez-Santiago, S.; Diaz, N.; Barnadas, A.; Cantos, B.; Mingorance, I.D.; Ezquerra, M.B.; Martin, M.; Martinez, N.; Vicente, E. Interim results from CompLEEment-1 (A phase IIIb study of ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population): Spanish cohort results. ANNALS OF ONCOLOGY. 2019. DOI: 10.1093/annonc/mdz242.031

  • Mcneish, I.A.; Moreno, V.; Jayson, G.; Roxburgh, P.; Ginesta, M.P.B.; Garcia-Donas, J.; Anton Torres, A.; Michael, A.; Brown, R.; Krige, D.; Bendall, J.; Di Genova, G.; Mcelwaine-Johnn, H. OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer. ANNALS OF ONCOLOGY. 2019. DOI: 10.1093/annonc/mdz250.039

  • Aguilar, E.A.; Foncillas, J.G.; Anton, A.; Herrero, C.J.C.; Mena, A.C.; Figueiras, M.C.; Hernandez, J.J.C.; Rubio, E.D.; Gascon, P.N.; Porta, V.G.; Lopez, R.; Feyjoo, M.; Puente, J. Clinical practice evaluation of opioids induced constipation management in cancer patients: The EIO-Praxis project. ANNALS OF ONCOLOGY. 2019. DOI: 10.1093/annonc/mdz265.064

  • Perez, J.M.T.; Subbiah, V.; Besse, B.; Moreno, V.; Lopez, R.; Sala, M.A.; Ponce, S.; Fernendez, C.; Nieto, A.; Kahatt, C.; Zeaiter, A.; Zaman, K.; Boni, V.; Arrondeau, J.; Martinez, M.; Delord, J.; Awada, A.; Kristeleit, R.; Longo, F.; Sarantopoulos, J.; Rubio, M.; Anton, A.; Wannesson, L.; Valdivia, J.; Shappiro, G.; Villalobos, V.; Santoro, A.; D''arcangelo, M.; Aparicio, L.; Paz-Ares, L. Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring >= 30 Days After Last Platinum Dose. JOURNAL OF THORACIC ONCOLOGY. 2019. DOI: 10.1016/j.jtho.2019.08.1116

  • Cussac, A.L.; Perez-Garcia, J.; Guerrero, A.; Bermejo, B.; Gil, M.; Caranana, V.; Morales, S.; de la Haba, J.; Fernandez, M.; Alba, E.; Urruticoechea, A.; Calvo, L.; Margeli, M.; Anton, A.; Borrego, M.R.; Albanell, J.; Rovira, P.S.; Bellet, M.; Braga, S.; Coelho, P.; Abreu, M.; Cortes, J. Neoadjuvant letrozole and palbociclib in stage II-IIIB HR[+]/HER2[-] breast cancer with Oncotype DX Recurrence Score (R) (RS) 18-25 or 26-100. Analysis of RS changes at surgery (DxCARTES trial). CANCER RESEARCH. 2019. DOI: 10.1158/1538-7445.AM2019-CT219

  • Ruiz-Borrego, M.; Jimenez, M.M.; Ruiz, A.; Lluch, A.; Ramos, M.; Jurado, J.C.; Baena-Canada, J.M.; Cirauqui, B.; Rodriguez-Lescure, A.; Conejo, E.A.; Janez, N.M.; Munoz, M.; Antolin, S.; Lopez, I.A.; del Barco, S.; Garcia-Estevez, L.; Lopez-Muniz, J.I.C.; Torres, A.A.; Carrasco, E. Phase III evaluating the addition of fulvestrant (F) to anastrozol (A) as adjuvant therapy in postmenopausal women with hormone receptor positive HER2 negative (HR+/HER2-) early breast cancer (EBC): Results from the GEICAM/2006-10 study. ANNALS OF ONCOLOGY. 2017. DOI: 10.1093/annonc/mdx362

  • Foncillas, J.G.; Tabernero, J.; Aguilar, E.A.; Benavides, M.; Camps, C.J.; Lopez, R.; Montagut, C.; Torres, A.A.; Vivanco, G.L.; Rubio, E.D.; Rojo, F.; Vivancos, A. First prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis. ANNALS OF ONCOLOGY. 2017. DOI: 10.1093/annonc/mdx363.045

  • Aranda, E.; Herrero, C.C.; Khosravi, P.; Feyjoo, M.; Torres, A.A.; Gascon, P.; Foncillas, J.G.; Rubio, E.D.; Porta, V.G.; Carrato, A.; Figueiras, M.C.; Hernandez, J.J.C.; Lopez, R. How do Spanish medical oncologists manage breakthrough pain? A national study. ANNALS OF ONCOLOGY. 2017. DOI: 10.1093/annonc/mdx388.044

  • Madani, J.; Herrero, A.; Eizaguirre, B.; Alonso, V.; Puertolas, T.; Lao, J.; Artal, A.; Anton, A. IMPACT OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND HYPOXIA - INDUCTIBLE FACTOR-1ALPHA (HIF-1) EXPRESSION ON RESPONSE TO RADIO-CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2017

  • Adrover, E.; Esteban, I.; Llort, G.; Servitja, S.; Peralta, S.M.; Garau, I.; Cano, J.M.; Serrano, R.; Fita, M.J.J.; Casas, A.; Grana, B.; Teule, A.; Marquez, A.; Martinez, J.E.A.; Antón, A.; Brunet, J.; Balaguer, F.; Gonzalez, S.; Balmana, J.; Alonso, C. Famosa: Evaluation of a multigene panel in patients with suspected HBOC. ANNALS OF ONCOLOGY. 2016. DOI: 10.1093/annonc/mdw364.32

  • Pajares Bernad, I.; Mártinez Trufero, J.; Calera Urquizu, L.; Cebolleo de Miguel, A.; Pazo Cid, R.; Lanzuela Valero, M.; Agsustín, M.J.; Millastre, E.; Santander Lobera, C.; Alvarez Alejandro, M.; Gimeno, N.; Malo Yague, M.; Llorente, Y.; Antón Torres, A.; Retrospective study of weekly paclitaxel-cetuximab (WPC) in unselected patients (p) with recurrent/metastatic head and neck squamous cell carcinoma (RM-SCCHN). ANNALS OF ONCOLOGY. 2016. DOI: 10.1093/annonc/mdw376.43

  • Haba, J. de La; Aguilar, E. Aranda; Morales, S.; García-Sáenz, J.A.; Guerrero, A.; Martínez, N.; Antón, A.; Muñoz, M.; Ramos, M.; Gil-Gil, M.; Margelí, M.; Servitja, S.; Bermejo, B.; Cruz, J.; Lescure, A. Rodríguez; Casas, M.; Sánchez-Aragó, M.; Caballero, R.; Carrasco, E.; Martin, M. ACE and CXCL10 as predictive biomarkers in the LEA study. ANNALS OF ONCOLOGY. 2016. DOI: 10.1093/annonc/mdw363.83

  • de Miguel Samaniego, D.; Pazo Cid, R.; Antón Torres, A.; Pardo, J.; Anel, A.; Martínez-Lostao, L. Liposomes decorated with Apo2L/ TRAIL induce apoptosis more efficiently than soluble Apo2L/TRAIL in human breast tumor cells. INMUNOLOGIA. 2013

  • Camps, C.; Anton,A.; Carrato,A.; de las Heras,M.; Manas,A.; Valentin,V.; Casas,A. Cognitive Function Association with Anaemia in Patients with Methastasic Or Advanced Solid Tumour Undergoing Oncologic Treatment - EVOLUTION Study. EJC SUPPLEMENTS. 2009. DOI: 10.1016/s1359-6349(09)70658-5

  • Anton, A.; Ruiz-Simon, A.; Plazaola, A.; Calvo, L.; Segui, M. A.; Santaballa, A.; Muñoz, M.; Sanchez, P.; de Miguel, A.; Cirauqui, B.;Arcusa, A.; Oltra, A.; Puertolas, T.; Guerrero, A. H. Phase II Study of a 3-Weekly Liposome-Encapsulated doxorubicin/docetaxel/pegfligrastrim in Combination with Weekly Trastuzumab as Primary Treatment in HER2 Positive Early Stage Breast Cancer Patients (II-IIIa). GEICAM 2003-03 Study. CANCER RESEARCH. 2009. DOI: 10.1158/0008-5472.SABCS-5117

Books

  • editor, Antonio Antón Torres ; coeditores, Alberto Anel... [et al.]. Inmunología tumoral e inmunoterapia del cáncer. 2018

  • [comité editorial, Eduardo Díaz-Rubio (ed.) ... et al. ; colabora, Asociación Española contra el Cáncer ; auspicia, Sociedad Española de Oncología Médica ; patrocina AMGEN ; participantes, Vicente Alberola, Antonio Antón ... et al.]. Glosario del cáncer. 2007

  • por Teresa de Jesús Puértolas Hernández ; directores, Dr. Antón y Dr. Maurel. Parámetros histológicos, de proliferación celular y genes implicados en la apoptosis, que determinan un mayor riesgo en el melanoma maligno cutáneo de buen pronóstico. 2005

Scientific chapters

  • A. Antón Torres Y J. Lao Romera. Urgencias oncológicas. CLÍNICA PRÁCTICA: GUÍA PARA ESTUDIANTES Y RESIDENTES. 2021

  • Antonio Antón... [et al.]. Manejo de toxicidades. INMUNOLOGÍA TUMORAL E INMUNOTERAPIA DEL CÁNCER. 2018

  • Antonio Antón Torres. La Oncología Médica como especialidad horizontal e integradora en medicina. MANUAL SEOM DE CUIDADOS CONTINUOS. 2010

  • Antonio Antón Torres, Raquel Casas Cornejo y Verónica Calderero Aragón. Cáncer de colon y recto. ENFERMEDADES ONCOLÓGICAS: CONSEJOS PARA PACIENTES. 2007

  • A. Antón, V. Alonso y J. Martínez. Cáncer de esófago. ONCOLOGÍA MÉDICA. 1999



© University of Zaragoza | Versión 2.26.9
© Computing and Communications Service of the University of Zaragoza (Pedro Cerbuna 12, 50009 ZARAGOZA - SPAIN)